TTNP - Earnings call transcript Q4 2019 | Titan Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for holding and welcome to the Titan Pharmaceuticals Fourth Quarter and Full Year 2019 Financial Results Conference Call. At this time, all participants are in a listen-only mode. There will be a question-and-answer session following today's remarks. Please be advised that this call is being taped at the Company's request and will be archived on the Company's website, starting later today.

At this time, I would like to turn the conference over to Sunil Bhonsle, President and CEO of Titan Pharmaceuticals. ahead. go Please

Sunil Bhonsle

XX, and to Andrea, and all joining year-ended for results on an Thank business. our Titan thank Pharmaceuticals’ Welcome December and quarter the the financial and call us. provide for update you, fourth you XXXX, to operational review

can we wanted provides the and these you website results, press issued today to Before summary our that our of filed and SEC, have begin, with found report annual the I a at the XXXX on inform on we be Form XX-K release titanpharm.com.

to this want to and scheduled. to also & at over tirelessly I issue team at remote weekend Titan, counsel audit take Loeb, these OUM, opportunity at reports their thank worked have including from staff on the who Loeb our locations, our the

everyone. to thanks So,

call Rubin, Vice President Joining Executive DeVarney, Dane and Crowley, Chief President are from today Chairman; Brian Executive me Dr. Hallberg, Titan on and Officer; our Administration. Scientific Kate Finance Dr. and the Officer; Executive and Chief Vice Commercial President of Marc Vice

go details forward-looking update will of an results provide Jennifer and Company, the on the the we Jennifer? required cautions review into statements. the regarding financial Before Kiernan

Jennifer Kiernan

Thank Sunil. you,

than conditions price. business, could statements limited involve our historical relating statements and matters commercialization forward-looking any facts. our Section operating affect to not the statements Exchange that want that results, everyone stock and not XXE other negatively and today, may XXXX, the Such development are are Section any Securities will of Act XXXX. to, uncertainties risks but statements of that XXA Securities information, certain include, remind discussed programs be other within to and and I statements the of of historical financial contain product that meaning Act of Such

management's any to include of and or the to to and Probuphine; candidates; commercialization current any expectations our process; Factors such is forward-looking patent cause risks and conditions from required testing, regulatory uncertainties relating obligation matters; by differ production the or intellectual our marketing the and change development, changes We based, circumstances ability agreements which access actual results those in or capital, of disclaim to any in and publicly any property any expectations that approval materially updates on could to Titan's drug or reflect events, statement release expressly undertaking law. herein any statements except to contained as relationships. strategic revisions

back to Sunil. now, And you,

Sunil Bhonsle

you, Thank Jennifer.

As and then overview Kate a updates opening followed always, Marc your we and summarize close product start financial Executive the regulatory Crowley results, Rubin, brief recap commercial from Chairman, will with I will updates medical an affairs, development questions. from by and the call for with then Hallberg, will Dane the Dr. Brian Dr. call our before from DeVarney.

let's started. So, Marc? get

Dr. Marc Rubin

and of to these times. very a and everyone, very who us able you join to much, you challenging thanks Sunil, all to Thank are hello special today during

Before the I'd we tell I you pandemic. to in COVID-XX doing about begin like are briefly response to what

remain healthy of hope stakeholders working at productive. our all Everyone communities measures working Titan in XXXX. precautionary and during and non-essential as we in To will be that and from components live growth sheltering of as including which of exclusively in is and the recommendations global safe At local, protected priority and and I of our our continue sincerely sales possible. organizations. that As safe business diligently pleased execute health to deeply situation am additional continue customers, evolve, committed remotely, and meetings, to is and as are we place to end, have switching same put time, with we keeping home, place, the from we Titan's virtual to work. we proactive employees, national the and monitoring safety our the and say plan health implementing to freezing to all everyone as and top We goal the well. remain continues travel,

XXXX. Throughout And on successfully made laid and important commercial overview we to to a an space to the the transition Turning progress year, we create of a number meaningful infrastructure the company. foundation we of initiatives. required to worked

some We process the or healthcare following: payers simplify refined ordering coverage with health shorten of segmentation to expanded And of and digital market available through REMS third-party evaluation with and third-party of specialty mitigation strategy; time of validated delivery. care the risk robust the the and our payors to of we which requirements providers. patients, key these include helps coordination among from REMS pharmacies our evaluation prescription we addition certified network and from utilized capabilities pharmacy strategies national hub We the a product to distribution streamlined all coordinate a benefits portal significantly initial product process, the and new conducted and the

of benefits, such degree and the the cover now number private insurance third-party and medical plans coverage pharmacy Probuphine. public insurance of than more offer We that other expanded XX% Probuphine under for payers plans some of and that

and our certified us have provider, well a company comprehensive, XXXX, of and We exercises regulatory given execute of new on very to positions pleased to resource our I'm progress Probuphine. continue patient year. healthcare rolled program. our We strategy via Subsequent providers implemented direct a to especially we we the faced. year-end, team's and grew and sheet with programs, caregiver education out registered during strengthened compliance the growth during healthcare constraints number balance that as of offering the that warrants a we

XXXX was closing establishing remarks. will in global an product. program the update on brand true Sunil a of as in his An the Commission's -- the global is provide EU, product this European important for this milestone Sixmo, approval which the name

announce National Nalmefene provide second ProNeura a we were Kate front, details program. for or Drug our NIDA's very on to in will pleased Abuse’s more the the And tier On Institute few of that funding for approval minutes.

possible and as healthy. stay as of to again, much stay all stay please once safe, Finally, you listening, home

on and the call activities And Dane, will will progress with that turn elaborate and he commercial Dane? that made. now team have the I who his our over to

Dane Hallberg

Thank much, very you Mark.

our During commercial our increased relationships hub on new and specialty our services and was to force grow added federal XXXX, capabilities. patient via improved necessary infrastructure our to build marketing We programs coverage network, pharmacy partner, sales our expanded include initiatives agencies our our focus establishing to and span.

As a number an of Probuphine. marketing efforts, we and in prescribers coverage result increase these the sales are have and both, realized of

their with remains commitment customers, environment even to in current our this and Our caregivers COVID-XX. patients strong,

implemented teams, strategies OUD. sales, have our and tools of that hub provide support medical the treating and all field We to REMS, to in continue allow field

three Specialty of to Prime, more Pharmacy, a disruption highest and implemented presence product CVS months Accredo specialty U.S. from opioid number AllianceRx network which hub has those of Scripts, Express and chain also states pharmacies, reduced management subsidiary We've reporting prescription to we Walgreens number two partnership U.S. weeks. pharmacy, to Caremark, in in national partnerships, through improved largest mentioned, regional among established a and process a AppianRx with I related largest two delivery a Texas. our the one the efficient the As that and California These deaths expanded patient We've time the and a strong with the minimal supply with specialty are among our services services Health the of prescription specialty pharmacy pharmaceutical business CVS subsidiary U.S. Southside a of in of

locating our highlights launch access healthcare unique included and campaign, healthcare providers. the of qualified XXXX of treatment their Probuphine Step long-term website so the provider branded easier into a provide improved patients features visibility, also Stability and portal and patient which branding and saw to caregivers

It We also executed schedule went a a XX, term. pricing XXXX. supply agreement that federal has January effect five-year into

currently others system, Probuphine for our another their within are the VA federal VA a offering We solution to OUD elect to and virtual to protocols in who treatment training beneficiary for establishing veterans program need. clinicians, add

will marketing our expanded personnel we the with account our in geographies, sales and managers support Recently, ability service senior grow sales key Probuphine-related which customers and addition of to revenue. capabilities enhance our and

had We number of product achieved of a XXXX, the providers and partnerships. distribution some active product through strategic date. broad utilizing healthcare continues active At to access prescribers, and end summarize To accomplishments key by XXX increase. steadily network our we to of comprehensive the

increase significantly prescribing product providers We and growth continue an to patients. XX.X% versus our We QX see our and in the between QX. time in for availability reduced with prescriptions

reducing barriers are to proactively therapy. We

than Centers reimbursement legacy may these rates out treatment. the insertion maximum Medicaid the and CMS. do private Specifically, the payer Services, oftentimes for not This patients of Probuphine Medicare from The reimburse also unfairly adequately as pocket known of healthcare as receiving to rates providers or it allowed. the and fairly costing and pertains removal, for procedures, appropriate prevent many CMS current more

leaders. and engage We CMS are to adequate and discussion honest fair opinion to frank reimbursement regarding with actively a key trying have

to our via Probuphine patient goal XXXX and insert fortified short who Probuphine goal support option the continue fell broad XXX focus their only model our elect support of main model. behalf. will prescribe we the While product those of by with be to our prescribers certified of to clinicians number This to have of throughout clinicians achieving increase year-end, to remove active prescribers prefer REMS access the on will

hurdle partner, the currently along on with compliance out prescribers nationwide of and model medical, hub and matrix patients include This model for the our with support foundation teams is of clinicians was that support soft select potential is updated growing with in a patient and under geographies launch the Our another goal marketing. created year-end, our of built goal REMS, alike. of removing by

on efforts and and to our existing can our of as commercial office, PR, and country organizations in caregiver our to plans in highly and via can mentioned, our very as commercial as serve professionals of pivoted remotely Probuphine. has patient telemedicine, training protect commercial of implemented impacted In channels, key support operations, to the unfettered to our we their around As updated clinicians field quickly changing to several bring they access new or to support talent our We the environment, our reimbursement, support marketing, patients as crisis areas COVID-XX as majority well thoughtfully in quickly sales phone, have By the world. skilled our customers, virtual patients. we been any all Marc employees move added team sales means. so via well senior light our by quickly rapidly initiatives activities of who the now have continue ensure work providers,

Finally, and proposition for call I'd light action of medication my mind share delivery, value stronger enhanced. in as providers improve thoughts continues of COVID-XX patients are pandemic. steady patient and and the peace to greatly compliance, like alike, grow the to to the Probuphine’s of

to of our course, of trying Titan needs are part our efforts relentless support our successfully for caregivers, and employees. a critical times navigating and patients, these providers, Our customers their our

on progress turn medical Officer, Dr. well our Titan's the functions I DeVarney, will our product compliance regulatory call safety will Scientific Chief our who as Kate? to as development over affairs, drug and Kate activities. discuss and

Dr. Kate DeVarney

you, Thank Dane.

$X.X implant approximately of program we provides the mentioned, The for manufacturing, pleased expense funding year second NIDA Nalmefene aggregate announce prevention commencing following the reimbursement funds for prior approved million, formulation clinical Marc is studies completion to for of were an development, approximately opioid million the detoxification. required to to GMP Titan As IND. relapse potential any our in development studies which $X.X under nonclinical that and

conducting are We this an pre-investigational and or recently our plans application year regarding end the the guidance a drug studies with in participated currently review early meeting filling new and obtain XXXX. of nonclinical FDA their by IND new development to in

has us Army collaborate testing to funding with this nonclinical forward Institute Institute platform testing these ProNeura the grant if from animal collaboration of promise formulations, also of studies. early formulations preparation to data compounds prophylactic shown Southwest both, have WRAIR other from continue in Defense atovaquone the In which for nonclinical of the is we prophylaxis, and with of is in to the evaluation Reed early available commercialization. additional Research SwRI for received SwRI, that proguanil and encouraging pursuing the other Research for or could and ProNeura the for activities, malaria or Walter as program additional WRAIR additional WRAIR Department the potential to and development malaria of collaborating we for successful, a and be large WRAIR the implant funding look treatment with continue

Probuphine our to shifting now And activities.

the Our providers health compliance and has safety focused to across on medical Probuphine training certification team been drug and care affairs country. providing

so. training and support attended Probuphine we conferences pleased and raise also team, we health been multiple interest on XXXX, medical REMS training commercial During resources and our very with providers’ do in providing of were to professional will care to awareness the We've to we and participation continue sessions. REMS focusing

the in postponed quarter. resources. X call, last Phase Now, our to we in mentioned FDA have as our we our with effort the discussed a conference I preserve plans last on have call studies an And

over I'd care how the patients. monitoring like Before the treating to is exactly about disorder impacting briefly how health use turn COVID-XX call to I Brian, talk opioid are pandemic and providers

People with one opioid for mortality only comprise other diseases. during the risk of but COVID-XX, and from from most [ph] morbidity this addiction use vulnerable their disorder underlying populations pandemic. comorbid at potential Not and

So, critical medication assisted emergency. threatens patient access who treatment. therapy the to Probuphine evidence-based safely other it's curtail and treatments ongoing to context and that like consistently in to the people able need are emergency COVID-XX of receive addiction And this them

I used our SAMHSA, visits. place have Services are spoken that At of the DEA informed it that now this health Mental new and request have providers the for grant to in Enforcement exemption be of paradigm me announced care Administration would Probuphine using Health initial an some treatment effectively. of of Drug or the they in-person Agency Substance with Abuse telemedicine who

during While this difficult impact working our and for healthcare not we business, barriers we evaluate patients providers time. this both may are rapidly are ensure removal the and how insertion procedures that to

in training virtual a We're program. developing of the REMS process

creating trained may it So, finalized. be pandemic. we patients safely the with And program prescribe can also administer where once Probuphine. This providers to corona shared FDA to Probuphine treatment the during and continue clinics are be will receive healthcare is specialty

remarks keeping progress That next And concludes I for months. look updated the to my on our forward several you over today.

Titan's Brian? financial call the I'll results. discuss turn Brian to to Now,

Brian Crowley

Kate. you, Thank

therefore few of provide Please financial rounded note are I'll time, XX-K results numbers to At release with a was been all details today summary provided I'm our in have and available that filed SEC. are in issued press the key A our about Form earlier the and the just items. this approximate. highlight

$X.X with included revenue. NIDA revenue product in same grant. the we This which period in during was intellectual of related sales, rights and the sale ago, million related of reported of million amortization fourth the $X.X to comprised to million XXXX, of related the $X.X $X.X $X.X This Molteni quarter $X to million In the European product of $X.X from million Probuphine deferred the sales, million grant. compares revenue our in property to to of NIDA related year a million

to revenue, sales This total million and license $X.X in million The XXXX sales million non-recurring license increases of to by million compares of revenues our offset revenue resulted million which of upfront XXXX, to $X.X million the in XXXX, license the were from revenues and XXXX. $X.X $X.X our which partially license million, grant. licensee, decrease Total remaining rights related $X.X Probuphine or $X amortization of which $X.X million year-ended to million included in payment of Molteni, in of revenues, revenues XX, million from million, to $X.X grant. XXXX for NIDA related $X Probuphine million revenue, December related upfront $X.X in million $X.X $X.X our milestone represented primarily revenues million includes from Probuphine was and and -- product from payments during which Molteni Probuphine and $X.X in a of the requiring or grant the during from $X.X former NIDA

$X were expenses in quarter, in sold, operating quarter consisted goods $XX.X operating in SG&A the expenses with primarily were total inclusive XXXX, XXXX million of $X.X the million and year R&D expenses. distribution of same and to For million primarily expenses R&D SG&A the and cost Total compared $XX.X for expenses and in of million full fourth consisting of XXXX. compared

in and development the year-ended $X.X $X.X to XX, partially with grant million NIDA the associated contract primarily manufacturing by December our compared XXXX, and million costs. to in employee-related costs was activities research decrease increase XXXX in and increased related in decreases other expenses an R&D expenses R&D were for the offset expenses,

associated expenses increase commercial ordering higher infrastructure was for XXXX. establishing Probuphine Probuphine expenses expenses streamline of SG&A network to with The the and to expanding the sales $XX.X distribution SG&A related increased and to and in $X.X million million activities. Titan’s compared XXXX expenses were marketing primarily due to

The of loss -- XXXX, full net The for $XX.X the share quarter net in XXXX. applicable share net net per million, per loss in $X share to XXXX. per full-year loss in our the was for of $X.XX of with was or quarter million, loss million, or the year $X.X million, or $X.XX $X.X same shareholders with a the share XXXX compared of per $X.XX fourth or $X.XX common compared

of believe the received fourth January the At are the of XXXX our we and of quarter million warrants into and proceeds from the cash during fund XXXX. December quarter which first to XX, with exercise had million, XXXX, operations planned $X offering cash sufficient of XXXX along equivalents cash net we the $X.X of

call the back to pass Sunil. I'll Now,

have to the any at Q&A happy the end the presentation. address you If of questions, I'll Sunil? be them during

Sunil Bhonsle

Thank you, Brian.

So, begin our providing let Europe. our Knight with Molteni Farmaceutici Canada, two and Therapeutics by summary activities partners, of a in in me

access focused obtaining patients. Saskatchewan formulary disorder During this Manitoba in opioid provincial Quebec, And Knight listing this past authorities. Scotia on Alberta, joined year, and approvals health early for use Newfoundland, Brunswick, Nova treatment year, eligible the Probuphine providing New the pricing to as provinces a in was and from product of

while they Ontario especially ramping product is continue and listings in activities remaining these promotion Knight their Columbia. up British to in provinces the provinces, pursue

first during And Probuphine trade applying the the name of towards which of first and European Molteni steps in in half which pricing registration expected approved know, the of Agency is year. Probuphine commercialization countries, partner Medicines for next specifically the the you for our by As the June XXXX. was Europe, this late in commenced key Sixmo, are product approval

with work plan implants with completion the environment schedule and very the facility schedule. contract the we're production the on to have modified the modifications EU very all of the U.S., the and hoping to nearing Now, team is in manufacturer at at day regulations. and the San day will will our meet production caution the monitoring This word that however, remain shortly. coronavirus of some the that working manufacturing with DPT buprenorphine has required Antonio spreading been of A of across Molteni the at to changes facility closely we qualification DPT,

be packaging at affected will the testing the hope of that of headquarters product to Also, and of kits the the one the like some we as with in planned activities. works Molteni, time, to their countries present complete Italy, worst launch scheduled able enable

you keep along will We months. few the posted developments over we go on as next

just Now, of a quick year. summary last

a During progress. with from XXXX, and good work our Titan Probuphine focused our hard on executing our strategy. we And lot was have keenly of made relaunch team partners,

the XXXX million of in the second While product of revenue as have the $X now averaged the same pace about XXXX, infrastructure half in we place.

expand continue patient expanding to support out operations practitioners as process, strengthened the marketing who our through have and mid-level streamlining distribution commercial additional training undergoing and assistants, to sheet, providers well-positioned pharmacy maintenance targeted the population efforts balance physician nurse a With to healthcare specialty treatment. we're such reach and and providers Probuphine

I set implementing patient be described. removal insertion Dane the best excited for to other allowing community am suited and strength of perform to without by in procedures. Probuphine performed trained permitting system to to about It healthcare that and up to support prescribe providers it fortified those that having healthcare patient many the utilizes the and procedures providers, the qualified particularly model the the

the healthcare that patients choose with I right could oriented providers Also, of approach by initiatives right and territory all. patients. supported they social providers medical the help treatment science media like number for Probuphine. sales be provide their the a care there long-acting believe a and together, team. products marketing win-win are this may for health are liaison service and well The can the And managers

support. implant virtual hopefully working the be the progressing Kate for providing all in Also, And innovative, we year. and get is health training her their team are process our to diligently this with NIDA an by to team to beneficial providers IND, project necessary developing that ongoing current should end an Nalmefene for non-clinical the data environment. of thank the care file very

and somewhat careful my are six-month Including shareholder the within keep limited a with maintaining time an our XX% caution, expenses Board environment in growth management coronavirus reduction the by rapidly A the the Marc’s use Our and sentiment salaries, and present waters recognize we pandemic. word same changing time, uncharted at wisely in means. while the environment our business. being for of to the however, at the created resources are and of

way employees mind priority navigate the and to our safety trying partners, while be the first always importantly, providers in our these of the and must healthcare keeping that obstacles, We're the through most patients.

goals. you our to best our will we keep will do We And as to try always, reach updated.

prepared This for today. concludes our remarks

to Titan's take from Before executive the like we time. work Board, dedication this continued the I difficult ready during and and staff call questions open management thank the for Andrea, to questions, are hard I'd to participants. call

Operator

We question question-and-answer will comes the Instructions] our go of Please ahead. Zacks session. Dushyanth Anita And from first Investment now begin Research. [Operator

Anita Dushyanth

afternoon. Hi. Good

say that First today John congratulations Zacks. pass from for DeVarney to on want to And the Dr. of to on Board. just the appointment her I I’m filling please all, in

Do that veterans already show Probuphine? comprise was of have I of questions resources federal any Just how market couple supply Probuphine schedule? for you answered to many have the recently added a you few. know, a the addressable here.

Sunil Bhonsle

I Hi, know is for Anita. same time for are time. this at appreciate. John. results providing many financial you the in their there companies I Thank where filling calls

kind at that know, with of address of Dane suffering do that that? of system, those I Dane, In numbers specific population. want terms of the part to specific looked are VA you OUD has

Dane Hallberg

in greater the thanks by And of for are Thank question. they OUD. at the Sure. VA about you. affected Essentially, affected terms being Anita the with XX% veterans,

reach at is we to a But haven't sources at the not are population. we But X number XX% from specific veterans The the need general know looking available, that of is OUD. million I We million granular the general impacted what look data about But can impacted than a at overall yet. over is a affected by So, OUD, as know know are do number We at the get rate by more that data. we that population veterans impacted rate are total higher X numbers. whole -- than those we greater that it population. seen veterans. a the that those published significant.

know one who ensure to So, is is was use that we reasons the that -- Kate what government do that have the able ensure appropriately of to so. the to we we're have practices which doctors left contract to at that why moment. access we and to train wanted with with Probuphine in the their But

Anita Dushyanth

Okay. VA the from And who schedule? besides pull the might

Dane Hallberg

Well, the FSS is the Schedule. Federal Supply

any to federal procedures the have in normal that the request access would potentially get obviously the Probuphine. then trained So, FSS, utilizes to to TRICARE, get any and They -- just reimbursement. have put agency could put that the

Dushyanth Q - Anita

your the U.S.? regarding so discussions favorable if as some have you Europe of to throw discussions pricing Probuphine. And light also, Okay. far? pricing been And the Could be on in compared how will

Sunil Bhonsle

Hi, Anita.

that In of Europe, handles directly. really terms pricing Molteni in

this aware Europe. is treatments the quite that's able XX% to into level to be the they of appropriately so there. than Europe. appropriate of of healthcare spread While typical as an which substantially be show and two, on three countries they get, UK. And in such expect currently that At because has the pricing they policies will that initially It benefits pricing. of markets range those of And rest or establish to the say Germany, will somewhere provide have expectation That's European less in -- be I'm the pricing let's in systems higher the U.S. price, generally focused the available the product. where the Molteni the than probably the where of stage typical product higher the allows pricing of to of product that is

it's a as that will be go taken they very-staged approach So, forward.

first you. environment partners the is other into with do and on who where in once pricing already can use regions and Europe can countries creates mind specific ground targets very work set, you boots the two, So, the the the three with actually of have spread it

that guidance So, that's -- will of some six will as being have Molteni the I in maybe currency strategy obviously, in pandemic, the kind what participate of our Molteni direly with one following. in clearly from the really Italy next -- calls, maybe well. by of But one the but months, affected and be these calls, expect we partners provide

Anita Dushyanth

to My question the prescribers. was of kind other active related

call it. probably But, in was kind I prescribers You XXXX. mentioned working your XXX the What number said as end missed towards that there of looking maybe you're were and you year? target this of at you're active of

Sunil Bhonsle

Yes.

started still continuing reasons -- at when middle to grow. have, this, target of that XXX original prescribers well, we year the to stage this Our at are active really the are where would we various is but like that looking at said, we we we for the numbers the mentioned, they

we'll doubts get no XXX numbers, about it. to -- So, will I've see the we

we removal for implants. will at certain of process said, We centralized that to and ability process, of the the establishing, help utilize looking that the are in a expedite the sort models especially as insertion

doing paradigm faster. we do that. of services We the those lot who learned, active things like want implement that the capabilities procedure they're So, way, every ways trying the let who where trained and product be the prescribing procedure can like to the focus these use to and the getting on to physician product, those needs who use mean, not prescribe prescribe it expand not and change And to are healthcare move Dane the faster. have team can and these of providers can that his these. a to number I we the of to

Anita Dushyanth

rates request? approval the are for of prescription kind And what the

Sunil Bhonsle

approval say is rates, that…? terms payers, of through third-party you in When processing the

Anita Dushyanth

Yes.

Sunil Bhonsle

to want you Dane, do address that?

Dane Hallberg

Yes.

the the to haven't. a approvals. again, provided whether it but of approval. on the on that's it It others really So, Medicaid. with really the barriers, XX% I we is XX%, payer, But, have have in on I steps we benefits. but or rate very exception, reduce every upon depends then benefits the patient -- know depends is terms on would medical guess, upwards any rate It's coverage But a But medication. success say, it PAs, they really high dependent toward do benefits, by in the a coverage we individual we and drug. of have about medical acceptable as the benefits clinician very dependent high, states, the patient’s that the private side for individual patient’s XX% very Many

Anita Dushyanth

last share on for Do have just any And website metrics you performance? one question your me. to portal

Dane Hallberg

you performance, clarify? could The portal

Anita Dushyanth

Yes.

kind of were for thing? telemedicine You the going online

Dane Hallberg

on portal before with publicly So, us and are to we those within -- the but the we way -- internally those. for paper have But private prescribing Sunil prescriptions, That's enroll publish utilize that's other firewalled for physicians clinicians plan a available to for physician do and have We portals, from and the providing instead area, with firewalled we patients part portal most that public. based of to metrics process. that team. those reviewing the from -- the don't

Operator

comes Our Please question next ahead. Group. of from Jason go McCarthy Maxim

Unidentified Analyst

the here. I had It's question line Dave a Jason. for on just

you shed trials? the hold Phase trials on clinical Could of in light actually X the on pandemic. temporarily post-market color have on earlier been any these when mentioned You initiate you that put COVID-XX

Sunil Bhonsle

have one clinical and Kate two three give of color the actually But, Kate? Sure. then that. some studies, there we mean, think around participate I postponed. let and will in I you which were been I’ll

Dr. Kate DeVarney

And and due are small different studies used to implantation a will on previously clinical So, put into resources is our that -- Pharmacokinetic into re-implantation that doing hold study, we a at look currently. site we have we’ve study. abdomen giving also alternate a got that lower the study that's site. two committed One clinicians a and to post-marketing

implant that's and larger study cohort. in study at large safety Another looking observational is

Now, now until expensive, we conserving we clinical our are studies all time and right them. right can are studies when resources as initiate these are the is

We have been has the this. study in of And so very supportive FDA regular far communication been regarding FDA the with timelines.

in a The space. buprenorphine have by collaborate third study that of we been the some with our the study to companies FDA asked safety is cardiac other

So, that. of we're doing process in the

don't I starting we kind review be that the have FDA may a on what that impact study. the environment under protocol timelines. know currently the is have We the and coming months final pandemic in study at current of will anticipate that

in you imagine, is quarantine extreme have isolation you for As when social really a especially and of challenging, to age subjects. a even doing do can study clinical an perhaps surgery

that's figure that as point I we say really can those about out. studies. keep all you at we'll this And of all So, updated

Unidentified Analyst

Okay. No, given for to sure, it's definitely understandable, -- times in that it’s now. we're difficult right the

point Earlier compared ‘XX. XX.X% here. to clarification prescribers on that active of correct? quick you guys XQ increase Is an another you mentioned in that saw Just

Sunil Bhonsle

to? want in... increase Yes, you The address percentage prescriptions. referring what That's to that? do the were you of Dane,

Dane Hallberg

the Can you state again, please? question

Unidentified Analyst

got point a down just make the I clarification. wanted to I number Just of sure correctly.

Is you You in right? mentioned active XX.X% in that compared an QX prescribers ‘XX. to that XQ saw ‘XX increase

Dane Hallberg

XX.X% QX. prescriptions. No, enrollments the were actual -- increased -- the those That prescription prescriptions in correct. The QX yes, versus

Unidentified Analyst

great. Okay, I appreciate it. Thanks a lot, guys.

Dane Hallberg

Sure.

Operator

over This Sunil any concludes I the for question-and-answer back session. our like conference remarks. would to Bhonsle turn to closing

Sunil Bhonsle

that the appreciate will to the time much that much excellent well this team facing. Probuphine hard products Thank take our ProNeura very is you, and times express technology program, have in our Thank your truly during very Andrea, to you like develop as care appreciate work would And ongoing truly day. of as world call. somewhat we using Titan taking support. for advance difficult and from pandemic. participating at this and thank safe, We this your stay you whole the I health, your I an all all you

Operator

now for conference and The Thank concluded. today's disconnect. now has attending may presentation you you

Titan Pharmaceuticals (TTNP) 30 Mar 202019 Q4 Earnings call transcript